MyoKardia

MyoKardia

MyoKardia

Dedicated to revolutionizing the treatment of genetic heart disease. Focused on cardiomyopathies
Founded
2012
Raised
$94M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$46,000,000
Venture capital (Series B) - 2015
Casdin Capital Cormorant Asset Management BridgeBio +2
$10,000,000
Venture capital - 2014
Team Size
50+
Employees
Xconomy

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia

Xconomy

MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021

the home of AI info

Minerva Neurosciences Inc. (NERV)'s Financial Results Comparing With MyoKardia Inc. (NASDAQ ...

the home of AI info

Minerva Neurosciences Inc. (NERV)'s Financial Results Comparing With MyoKardia Inc. (NASDAQ ...

Xconomy

MyoKardia Goes Solo as Sanofi Ends Precision Heart Drug Deal

Xconomy

MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring

Health
Xconomy

Despite Sanofi’s Help, MyoKardia Prices IPO Below Expectations

Health Stock markets
Xconomy

Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO

Health Funding